Drug company advertising in medical journals about the health-economic advantages of their products for 2000-2006 versus 1990-1999

Journal of Managed Care Pharmacy

Volumn 14, Issue 8, 2008, Pages 749-755

  Palmer, Jennifer A ^a   Timm, Alison R ^a   Neumann, Peter J ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FORMULARY; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; ECONOMIC ASPECT; FOOD AND DRUG ADMINISTRATION; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; HYPOTHESIS; INFORMATION PROCESSING; MEDICAL LITERATURE; PATIENT CARE; PRESCRIPTION;

EID: 56049104946     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.8.749     Document Type: Article

References (29)

1. Fugh-Berman A, Alladin K, Chow J. Advertising in medical journals: should current practices change? PLoS Med. 2006;3(6):e130. Available at: www.medicine.plosjournals.org/archive/1549-1676/3/6/pdf/ 10.1371_journal.pmed.0030130-L.pdf. Accessed September 25, 2008.
2. Lohiya S. Pharmaceutical advertisements in medical journals received in a medical clinic: are we having "too much of a good thing"? J Natl Med Assoc. 2005;97(5):718-20.
3. Herxheimer A, Lundborg CS, Westerholm B. Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards. Int J Health Serv. 1993;23(1):161-72.
4. Neumann PJ, Zivin BK, Ramakrishnan V, Stewart KA, Bell CM. Economic messages in prescription drug advertisements in medical journals. Med Care. 2002;40(9):840-45.
5. Villanueva P, Peiro S, Librero J, Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. Lancet. 2003;361(9351):27-32.
6. Kopp SW, Bang HK. Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications. Health Mark Q. 2000;17(3):39-56.
7. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med. 1992;116(11):912-19.
8. Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist. 2006;11(2):90-95.
9. Cooper RJ, Schriger DL. The availability of references and the sponsorship of original research cited in pharmaceutical advertisements. CMAJ. 2005;172(4):487-91.
10. Gitanjali B, Shashindran CH, Tripathi KD, Sethuraman KR. Are drug advertisements in Indian edition of BMJ unethical? BMJ 1997;315(7106):459.
11. van Winkelen P, van Denderen JS, Vossen CY, Huizinga TW, Dekker FW. How evidence-based are advertisements in journals regarding the subspecialty of rheumatology? Rheumatology (Oxford). 2006;45(9): 1154-57. Available at: www.rheumatology.oxfordjournals.org/cgi/reprint/45/9/1154. Accessed September 20, 2008.
12. Vlassov V, Mansfield P, Lexchin J, Vlassova A. Do drug advertisements in Russian medical journals provide essential information for safe prescribing? West J Med. 2001;174(6):391-94.
13. Greving JP, Denig P, de Zeeuw D, Haaijer-Ruskamp FM. Claims in advertisements for antihypertensive drugs in a Dutch medical journal. J Hypertens. 2007;25(3):713-22.
14. Gutknecht DR. Evidence-based advertising? A survey of four major journals.J Am Board Fam Pract. 2001;14(3):197-200.
15. Lexchin J, Holbrook A. Methodologic quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. CMAJ. 1994;151(1):76-80.
16. Stimson GV. The use of references in drug advertisements. J R Coll Gen Pract. 1976;26(Suppl 1):S76-80.
17. Loke TW, Koh FC, Ward JE. Pharmaceutical advertisement claims in Australian medical publications. Med J Aust. 2002;177(6):291-93.
18. Lankinen KS, Levola T, Marttinen K, Puumalainen I, Helin-Salmivaara A. Industry guidelines, laws and regulations ignored: quality of drug advertising in medical journals. Pharmacoepidemiol Drug Saf. 2004; 13(11):789-95.
19. Bhattacharyya T, Tornetta P, III, Healy WL, Einhorn TA. The validity of claims made in orthopaedic print advertisements. J Bone Joint Surg Am. 2003;85-A(7):1224-28.
20. Neumann PJ, Claxton K, Weinstein MC. The FDA's regulation of health economic information. Health Aff. (Millwood) 2000;19(5):129-37.
21. Stewart KA, Neumann PJ. FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation. Value Health. 2002;5(5):390-97.
22. Neumann PJ. What ever happened to FDAMA Section 114? A look back after 10 years. Value Health. 2008 (in press).
23. The AMCP Format for Formulary Submissions. Version 2.1. Foundation for Managed Care Pharmacy. Available at: http://www.fmcpnet.org/. Accessed September 20, 2008.
24. Safavi KT, Hayward RA. Choosing between apples and apples: physicians' choices of prescription drugs that have similar side effects and efficacies.J Gen Intern Med. 1992;7(1):32-37.
25. Reichert S, Simon T, Halm EA. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med. 2000;160(18):2799-803.
26. Ryan M, Yule B, Bond C, Taylor RJ. Scottish general practitioners' attitudes and knowledge in respect of prescribing costs. BMJ. 1990;300(6735):1316-18.
27. Friedman LS, Richter ED. Excessive and disproportionate advertising in peer-reviewed journals. Int J Occup Environ Health. 2006;12(1):59-64.
28. Cowden AL, Katz KA. Food and Drug Administration surveillance of dermatology-related and nondermatology-related prescription drug advertising in the USA, 2000-2003. Br J Dermatol. 2006;154(5):950-58.
29. Bartus CL, Katz KA. Advertising in dermatology journals: journals' and journal editors' policies, practices, and attitudes.J Am Acad Dermatol. 2006;55(1):116-22.